Slide 1: Letter to stock exchanges on investor presentation
RPG LIFE SCIENCES LIMITED L Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071 , India Tel: +91-22-25292152-55 Fax: +91 -22-25297423 RPO LIFE SCIENCES April 30, 2022 To The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Excha
Slide 2: Investors' Presentation Q4 and Full Year FY22
RPG LIFE SCIENCES An <>>>R~G Company Investors’ Presentation Q4 and Full Year FY22
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Life Sciences Overview
RPG Life Sciences Overview RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Leader in Immunosuppressants Domestic Formulations
Slide 5: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio Key Therapies Key Products Immunosuppressant Portfolio Text Book Brands New Portfolio Specialty Life Cycle Management Chronic • Nephrology Azoran· (Existing Products) • Rheumatology Azoran· Azathioprine Trastuzumab ·NuGliP.!1!! Domestic Azathioprine - -- -- -- --
Slide 6: Key Financials, Business Highlights & Strategy
Key Financials, Business Highlights & Strategy An <l>» RPCi Company 5 L R?G LIFE SCIENCES
Slide 7: Key Highlights of FY22
Key Highlights of FY22 RPGLS growing faster than the market at 20.5%% vs 14.6% (IPM)* Healthy double-digit growth in revenue from operations ~ Profit margins’ record-setting trajectory continues – EBITDA margin reaches 20% & PBT margin 17% FY22 records significant PBT margin expansion across the seg
Slide 8: Company Financial Performance – Profit Margins
Company Financial Performance – Profit Margins Upward y-o-y Record setting Trajectory continues – EBITDA Margin reaches 20% & PBT Margin 17% PBDIT% 20% 18% PBT% 16% 17% 14% 12% 11% 10% 10% 10% 9% 8% 6% 6% 5% 4% 4% 4% 4% 1% 0% 0% All numbers are rounded-off to full integers 7 An +» ,e;:,c; Company -
Slide 9: Key Financials' Trends
Key Financials’ Trends (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations - --t ___t EBITDA & EBITDA Margin PBT & PBT Margin - -t 89.4 440.2 73.2 375.6 389.1 70.8 330.2 59.9 53.6 41.8 34.4 15.1 FY19 FY20 FY21 FY22 n 10.4% FY19 15.9% FY20 18.2% FY21 20.3% FY22 4.6% FY19 11.1% FY20
Slide 10: Key Financials' Trends
Key Financials’ Trends _f ROCE% _f ROE% Debt/Equity Ratio - -l 27.9% 0.22 23.6% 24.3% 18.5% 20.1% 16.4% 11.0% 6.7% 0.06 0.01 0.00 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 Company continues to remain Debt-free An <l>» RPCi Company 9 L R?G LIFE SCIENCES
Slide 11: Business Segment-wise Performance: FY22
Business Segment-wise Performance : FY22 Sales (Rs Crs) • Domestic Formulations contributed 65% to total Sales of FY22 Domestic • 19% Sales growth majorly driven by Legacy Products Formulations • Better than Market growth despite Covid headwinds 280.9 235.4 • New Products Contribution* improved to 1
Slide 12: Key Financials: Q4 FY22
Key Financials : Q4 FY22 (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin - --t - --t - -t 16 14.8 10.9 103.8 15 9.0 92.8 14 13.0 13 12 14.2% 10.5% 14.0% 9.6% 11 10 FY21 Q4 FY22 Q4 FY21 Q4 FY22 Q4 FY21 Q4 FY22 Q4 PAT & PAT Margin EPS - -t
Slide 13: RPG Life Sciences ICRA Rating Reaffirmed in FY22
RPG Life Sciences ICRA Rating Reaffirmed in FY22 Long term rating reaffirmed at A Short term rating reaffirmed at A1 Outlook on long term rating has been retained as Stable The rating reaffirmation factors: Strong brands in the Indian Pharmaceutical Industry Considerable improvement in the opera
Slide 14: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leader in Immunosuppressant category • Good Customer Coverage - Cardiologists,
Slide 15: International Formulations (IF)
International Formulations (IF) • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and business relationship with some of the
Slide 16: APIs
APIs • High Value, Low Volume Niche APIs • Mature Stable Molecules • Provides backward integration to International Formulations business • Footprints across geographies - LATAM, Iran, Germany, China, South Korea, Bangladesh, Egypt, India, etc • Strong customer focus - Long lasting relationship with
Slide 17: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities An <l>» RPCi Company 16 L R?G LIFE SCIENCES
Slide 18: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the Domestic and Emerging Markets • Multipurpose plant with dedicated product lines for Oral Dosage forms including Tablets, Liquids and Powder • WHO, Kenya, Nigeria approved Formulations Unit 2, Ankleshwar • F2 unit caters
Slide 19: Strong Backend Capabilities
Strong Backend Capabilities 9 - • • Quality All Critical SOPs harmonized through CQA Quarterly Internal audit of all plants by CQA @- • Regulatory Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and Emerging markets • All critical deviations, change controls and
Slide 20: Operational Highlights
Operational Highlights An <l>» RPCi Company 19 L R?G LIFE SCIENCES
Slide 21: RPG Life Sciences response to COVID-19
RPG Life Sciences response to COVID-19 A passionate call to the entire organization to go all out to ensure continuous availability of our life saving, critical medicines to our patients. Our Plants did not stop even for a single day. Every patient, who asked for our critical medicines, serviced by
Slide 22: New Digitalization Initiatives to Transform Business
New Digitalization Initiatives to Transform Business Game Changer Customer Connect Initiative Employee Connect Initiatives Digital Platform for comprehensive ~ 2 .0 Salesforce Operations tracking: #Customer visits, customer engagement activities, sales performance analytics etc .- • Anytime, Anywher
Slide 23: People Initiatives to build Performance Culture with focus on Happiness
People Initiatives to build Performance Culture with focus on Happiness I Love My Work I Feel Valued I am Growing RPGLS Heroes Outperformance We Skill. You Grow. You Excel. We Applaud. Recognition Competency Building Motivation Continuum Continuum •• Akanksha 0 Career Development High Happiness I Li
Slide 24: FY23 Priorities
FY23 Priorities Maintain growth momentum in top-line and bottom-line across the business segments Continue to grow our presence in chronic and specialty therapies in DF through new product launches and new customer segments Continue to build iconic/legacy brands into strategic assets Continue to enh
Slide 25: Awards & Recognitions
Awards & Recognitions An <l>» RPCi Company 24 L R?G LIFE SCIENCES
Slide 26: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA 15th April 2022 Industry Recognition to RPG Life Sciences Best Patent Award Best Corporate Citizen Award An <l>» RPCi Company L R?G LIFE SCIENCES
Slide 27: RPG Life Sciences is one of India's Best Workplaces in 2020
RPG Life Sciences is one of the India’s Best Workplace in 2020 – Amongst Top 100 • Ranked 85 amongst India's 100 Best Companies to Work For 2020 • One of India's Best Workplaces in Biotechnology & Pharmaceuticals by Great Place to Work® Institute Best Workplaces"' 0 I in Biotechnology & Pharm ace
Slide 28: Media Recognition
Media Recognition • Not a single day Plant stoppage • Home Delivery of critical life saving medicines to all the patients pQRTfOU O Pf ' ' dard moneycontrol Business Stan ( 11 ic areas ft Coronavirus Markets v News v Portfolio Commodities Mutual Funds v Personal Finance v Forum v Media v Earth360 In
Slide 29: Thank You
T H A N K Y O U An <l>» RPCi Company L R?G LIFE SCIENCES